Compare Ascendis Pharma A/S (ASND) vs Bit Digital Inc (BTBT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Bit Digital Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Bit Digital Inc trades at $1.67 (market cap $599.01M). The key difference: Ascendis Pharma A/S is far larger — about 29.6× Bit Digital Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Bit Digital Inc nearer its low. Which is the better fit depends on your goals.
| ASND | BTBT | |
|---|---|---|
Market Cap | $17.74B | $599.01M |
Sector | Health | Technology |
52-Week High | $277.18 | $4.22 |
52-Week Low | $163.32 | $1.27 |
Enterprise Value | $18.11B | $888.32M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
BTBT trades at $1.69, showing slight positive momentum with a 0.6% daily gain, but faces a bearish technical outlook with 15 sell signals versus 3 buys. The company reported a net loss of $80.32 million in 2025, with revenue of $113.56 million, and has missed earnings expectations for three consecutive quarters. Recent strategic moves include a $100 million loan facility for WhiteFiber and a $20 million Ethereum purchase to bolster its asset position.
The outlook remains challenging due to persistent losses and negative profit margins, though analyst consensus is unanimously bullish with 2 buy ratings. Key risks include execution challenges in AI infrastructure investments, reliance on financing for cash flow, and sensitivity to cryptocurrency market volatility impacting its strategic asset holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Bit Digital Inc
Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.
Read more on BTBT →
